Urticaria laboratory findings

Jump to navigation Jump to search

Urticaria Microchapters


Patient Information





Differentiating Urticaria from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies


Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urticaria laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Urticaria laboratory findings

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Urticaria laboratory findings

CDC on Urticaria laboratory findings

Urticaria laboratory findings in the news

Blogs on Urticaria laboratory findings

Directions to Hospitals Treating Urticaria

Risk calculators and risk factors for Urticaria laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]


Laboratory evaluation can be used as a measure to determine disease severity, responsiveness to treatment and prognosis, in addition to their role as a diagnostic tool. Tests such as autologous serum skin test (ASST) and basophil activation test (BAT) are useful for detection of autoantibodies against IgE. Moreover elevated levels of c-reactive protein (CRP), erythrocyte sedimentation rate (ESR), certain interleukins and tumor necrosis factor-alpha have been reported in urticaria patients. Laboratory evaluations that can determine disease activity are autologous serum skin test (ASST), c-reactive protein (CRP) and IL-6.

Laboratory Findings

Interleukins Explanations
Interleukin 6
Interleukin 1
Interleukin 23
Interleukin 31

Markers to determine disease severity/prognosis
Markers to evaluate response to therapy


  1. 1.0 1.1 1.2 Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P (2019). "Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications". J Asthma Allergy. 12: 285–295. doi:10.2147/JAA.S184986. PMC 6759208 Check |pmc= value (help). PMID 31571935.
  2. Ye YM, Park JW, Kim SH, Ban GY, Kim JH, Shin YS; et al. (2016). "Prognostic Factors for Chronic Spontaneous Urticaria: A 6-Month Prospective Observational Study". Allergy Asthma Immunol Res. 8 (2): 115–23. doi:10.4168/aair.2016.8.2.115. PMC 4713874. PMID 26739404.
  3. Kolkhir P, Altrichter S, Hawro T, Maurer M (2018). "C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria". Allergy. 73 (4): 940–948. doi:10.1111/all.13352. PMID 29130488.
  4. 4.0 4.1 Kasperska-Zajac A, Sztylc J, Machura E, Jop G (2011). "Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients". Clin Exp Allergy. 41 (10): 1386–91. doi:10.1111/j.1365-2222.2011.03789.x. PMID 21645137.
  5. Ohtsuka T (2010). "Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria". Int J Dermatol. 49 (5): 579–84. doi:10.1111/j.1365-4632.2010.04384.x. PMID 20534097.
  6. 6.0 6.1 Kaplan AP (2017). "Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations". Allergy Asthma Immunol Res. 9 (6): 477–482. doi:10.4168/aair.2017.9.6.477. PMC 5603475. PMID 28913986.
  7. Tedeschi A, Lorini M, Suli C, Asero R (2007). "Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity". Clin Exp Dermatol. 32 (5): 568–70. doi:10.1111/j.1365-2230.2007.02450.x. PMID 17509061.
  8. 8.0 8.1 Puxeddu I, Italiani P, Giungato P, Pratesi F, Panza F, Bartaloni D; et al. (2013). "Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria". Cytokine. 61 (3): 741–3. doi:10.1016/j.cyto.2013.01.015. PMID 23433789.
  9. Kolkhir P, André F, Church MK, Maurer M, Metz M (2017). "Potential blood biomarkers in chronic spontaneous urticaria". Clin Exp Allergy. 47 (1): 19–36. doi:10.1111/cea.12870. PMID 27926978.
  10. Grattan CE (2001). "Basophils in chronic urticaria". J Investig Dermatol Symp Proc. 6 (2): 139–40. doi:10.1046/j.0022-202x.2001.00027.x. PMID 11764301.
  11. Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M (2010). "Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors". Clin Exp Allergy. 40 (6): 875–81. doi:10.1111/j.1365-2222.2010.03473.x. PMID 20214668.
  12. Atwa MA, Emara AS, Youssef N, Bayoumy NM (2014). "Serum concentration of IL-17, IL-23 and TNF-α among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test". J Eur Acad Dermatol Venereol. 28 (4): 469–74. doi:10.1111/jdv.12124. PMID 23451767.
  13. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L, Maurer M (2017). "Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria". J Eur Acad Dermatol Venereol. 31 (6): 964–971. doi:10.1111/jdv.14221. PMID 28299827.
  14. Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E (2018). "Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria". J Immunol Res. 2018: 5615109. doi:10.1155/2018/5615109. PMC 6280255. PMID 30584542.
  15. Greaves M (2000). "Chronic urticaria". J Allergy Clin Immunol. 105 (4): 664–72. doi:10.1067/mai.2000.105706. PMID 10756214.

Template:WH Template:WS